Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur Sells 5,209 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $4.10, for a total value of $21,356.90. Following the completion of the transaction, the chief operating officer now owns 205,832 shares of the company’s stock, valued at $843,911.20. This trade represents a 2.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Daniel Lesueur also recently made the following trade(s):

• On Thursday, April 3rd, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The stock was sold at an average price of $4.15, for a total transaction of $21,617.35.
• On Wednesday, March 5th, Daniel Lesueur sold 16,902 shares of Health Catalyst stock. The shares were sold at an average price of $4.52, for a total transaction of $76,397.04.

Health Catalyst Stock Performance

Shares of NASDAQ:HCAT opened at $3.97 on Thursday. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The company has a 50-day moving average price of $4.15 and a 200-day moving average price of $6.00. The company has a market cap of $278.74 million, a price-to-earnings ratio of -2.94 and a beta of 1.56. Health Catalyst, Inc. has a 12 month low of $3.56 and a 12 month high of $9.24.

Institutional Investors Weigh In On Health Catalyst

Institutional investors and hedge funds have recently bought and sold shares of the business. Quantbot Technologies LP purchased a new position in shares of Health Catalyst during the fourth quarter valued at approximately $29,000. Group One Trading LLC lifted its position in shares of Health Catalyst by 107.6% in the 4th quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock worth $31,000 after purchasing an additional 2,260 shares during the period. Aquatic Capital Management LLC bought a new stake in shares of Health Catalyst during the 4th quarter valued at about $63,000. Stoneridge Investment Partners LLC purchased a new position in shares of Health Catalyst during the fourth quarter valued at about $77,000. Finally, Martin Worley Group bought a new position in Health Catalyst in the fourth quarter worth about $78,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Wall Street Analyst Weigh In

HCAT has been the subject of a number of recent research reports. Royal Bank of Canada decreased their target price on Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating for the company in a research report on Thursday, February 27th. Canaccord Genuity Group reduced their price target on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 21st. Wells Fargo & Company lowered their price target on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a report on Tuesday, January 21st. Piper Sandler decreased their price objective on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 11th. Finally, Citigroup dropped their target price on shares of Health Catalyst from $7.00 to $6.50 and set a “buy” rating for the company in a research report on Friday, April 25th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $8.05.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.